[en] Although old molecules, alkylating agents and platinum derivatives are still widely used in the treatment of various solid tumors. However, systemic toxicity and cellular resistance mechanisms impede their efficacy. Innovative strategies, including local administration, optimization of treatment schedule/ dosage, synergistic combinations, and the encapsulation of bioactive mole- cules in smart, multifunctional drug delivery systems, have shown promising results in potentiating anticancer activity while circumventing such hurdles. Furthermore, questioning of the old paradigm according to which nuclear DNA is the critical target of their anticancer activity has shed light on subcellular alternative and neglected targets that obviously participate in the mediation of cytotoxicity or resistance. Thus, rethinking of the use of these pivotal anti- neoplastic agents appears critical to improve clinical outcomes in the management of solid tumors.
Research center :
CESAM - Complex and Entangled Systems from Atoms to Materials - ULiège Center for Education and Research on Macromolecules (CERM)
Disciplines :
Chemistry Materials science & engineering
Author, co-author :
Lajous, Hélène; University of Angers, University of Nantes, CRCINA INSERM, France > University of Liège (ULiège), Complex and Entangled Systems from Atoms to Materials (CESAM), Center for Education and Research on Macromolecules (CERM), Belgium
Lelièvre, Bénédicte; Centre Régional de Pharmacovigilance, Laboratoire de Pharmacologie-Toxicologie, CHU, Angers, France
Vauléon, Bénédicte; Centre Eugène Marquis, Université de Rennes 1, INSERM U1242, France
Lecomte, Philippe ; University of Liège (ULiège), Complex and Entangled Systems from Atoms to Materials (CESAM), Center for Education and Research on Macromolecules (CERM), Belgium
Garcion, Emmanuel; University of Angers, University of Nantes, CRCINA INSERM, France
Language :
English
Title :
Rethinking alkylating(-like) agents for solid tumor management
Publication date :
May 2019
Journal title :
Trends in Pharmacological Sciences
ISSN :
0165-6147
eISSN :
1873-3735
Publisher :
Elsevier, Netherlands
Volume :
40
Issue :
5
Pages :
342-357
Peer reviewed :
Peer Reviewed verified by ORBi
Funders :
Fédération Wallonie Bruxelles. Fonds de la Recherche Scientifique - F.R.S.-FNRS The Erasmus Mundus Joint Doctorate (EMJD) NanoFar
Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
Ye, W., The complexity of translating anti-angiogenesis therapy from basic science to the clinic. Dev. Cell 37 (2016), 114–125.
Yang, W.-H., et al. Revision of the concept of anti-angiogenesis and its applications in tumor treatment. Chronic Dis. Transl. Med. 3 (2017), 33–40.
Mezencev, R., Interactions of cisplatin with non-DNA targets and their influence on anticancer activity and drug toxicity: the complex world of the platinum complex. Curr. Cancer Drug Targets 14 (2015), 794–816.
Gibson, D., Multi-action Pt(IV) anticancer agents; do we understand how they work?. J. Inorg. Biochem. 191 (2019), 77–84.
Kelland, L., The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer 7 (2007), 573–584.
Johnstone, T.C., et al. Third row transition metals for the treatment of cancer. Philos. Trans. R. Soc. Lond. A Math. Phys. Eng. Sci., 373, 2015, 20140185.
Wishart, D.S., et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 46 (2018), D1074–D1082.
Yang, F., et al. Doxorubicin, DNA torsion, and chromatin dynamics. Biochim. Biophys. Acta 1845 (2014), 84–89.
Siddik, Z.H., Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. Alison, M.R., (eds.) The Cancer Handbook, 1st edn, 2002, John Wiley & Sons, 1295–1313.
Corte-Rodríguez, M., et al. Quantitative evaluation of cellular uptake, DNA incorporation and adduct formation in cisplatin sensitive and resistant cell lines: comparison of different Pt-containing drugs. Biochem. Pharmacol. 98 (2015), 69–77.
Shen, D.-W., et al. Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol. Rev. 64 (2012), 706–721.
Dasari, S., Tchounwou, P.B., Cisplatin in cancer therapy: molecular mechanisms of action. Eur. J. Pharmacol. 740 (2014), 364–378.
Stewart, D.J., Mechanisms of resistance to cisplatin and carboplatin. Crit. Rev. Oncol. Hematol. 63 (2007), 12–31.
Garrido, N., et al. Cisplatin-mediated impairment of mitochondrial DNA metabolism inversely correlates with glutathione levels. Biochem. J. 414 (2008), 93–102.
Galluzzi, L., et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis., 5, 2014, e1257-18.
Cheung-Ong, K., et al. DNA-damaging agents in cancer chemotherapy: serendipity and chemical biology. Chem. Biol. 20 (2013), 648–659.
Amable, L., Cisplatin resistance and opportunities for precision medicine. Pharmacol. Res. 106 (2016), 27–36.
Fennell, D.A., et al. Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treat. Rev. 44 (2016), 42–50.
Ostrom, Q., et al. Gene markers in brain tumors: what the epileptologist should know. Epilepsia 54 (2013), 25–29.
Van Thuijl, H.F., et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment. Acta Neuropathol. 129 (2015), 597–607.
Hegi, M.E., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352 (2005), 997–1003.
O'Grady, S., et al. The role of DNA repair pathways in cisplatin resistant lung cancer. Cancer Treat. Rev. 40 (2014), 1161–1170.
Hoebers, F.J.P., et al. Cisplatin–DNA adduct formation in patients treated with cisplatin-based chemoradiation: lack of correlation between normal tissues and primary tumor. Cancer Chemother. Pharmacol. 61 (2008), 1075–1081.
Chalmers, A.J., et al. Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. Int. J. Radiat. Oncol. Biol. Phys. 75 (2009), 1511–1519.
Eckert, F., et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiat. Oncol., 5, 2010, 55.
Wilson, G.D., et al. Biologic basis for combining drugs with radiation. Semin. Radiat. Oncol. 16 (2006), 2–9.
Reboul, F.L., Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Hematol. Oncol. Clin. North Am. 18 (2004), 41–53.
Tippayamontri, T., et al. Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model. Anticancer Res. 32 (2012), 4395–4404.
Miladi, I., et al. Combining ultrasmall gadolinium-based nanoparticles with photon irradiation overcomes radioresistance of head and neck squamous cell carcinoma. Nanomed. Nanotechnol. Biol. Med. 11 (2015), 247–257.
Tomoda, K., et al. Examination of gossypol-pluronic micelles as potential radiosensitizers. AAPS J. 17 (2015), 1369–1375.
De Felice, F., et al. Head and neck cancer: metronomic chemotherapy. BMC Cancer, 15, 2015, 677.
Goldberg, R.M., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol. 22 (2004), 23–30.
Carethers, J.M., Systemic treatment of advanced colorectal cancer: tailoring therapy to the tumor. Ther. Adv. Gastroenterol. 1 (2008), 33–42.
Oldenburg, J., et al. Testicular seminoma and non-seminoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 24 (2013), vi125–vi132.
Bellmunt, J., et al. Bladder cancer: ESMO Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (2014), iii40–iii48.
Lordick, F., et al. Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (2016), v50–v57.
Novello, S., et al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 27 (2016), v1–v27.
Marth, C., et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28 (2017), iv72–iv83.
Postmus, P.E., et al. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28 (2017), iv1–iv21.
Wilson, T., et al. Glioblastoma multiforme: state of the art and future therapeutics. Surg. Neurol. Int., 5, 2014, 132138.
Lombardi, M.Y., Assem, M., Glioblastoma genomics: a very complicated story. De Vleeschouwer, S., (eds.) Glioblastoma, 2017, Codon, 3–25.
Laquintana, V., et al. New strategies to deliver anticancer drugs to brain tumors. Expert Opin. Drug Deliv. 6 (2009), 1017–1032.
Zhou, J., et al. Novel delivery strategies for glioblastoma. Cancer J. 18 (2012), 89–99.
Fernandes, C., et al. Current standards of care in glioblastoma therapy. De Vleeschouwer, S., (eds.) Glioblastoma, 2017, Codon, 197–241.
Hanif, F., et al. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac. J. Cancer Prev. 18 (2017), 3–9.
Arshad, A., et al. Convection-enhanced delivery of carboplatin PLGA nanoparticles for the treatment of glioblastoma. PLoS One, 10, 2015, e0132266.
Garg, T., et al. Current strategies for targeted delivery of bio-active drug molecules in the treatment of brain tumor. J. Drug Target. 23 (2015), 865–887.
Vogelbaum, M.A., Aghi, M.K., Convection-enhanced delivery for the treatment of glioblastoma. Neuro Oncol. 17 (2015), ii3–ii8.
Cheff, D.M., Hall, M.D., A drug of such damned nature. 1. Challenges and opportunities in translational platinum drug research. J. Med. Chem. 60 (2017), 4517–4532.
Shi, M., et al. Convection-enhancement delivery of platinum-based drugs and Lipoplatin™ to optimize the concomitant effect with radiotherapy in F98 glioma rat model. Invest. New Drugs 33 (2015), 555–563.
Vogelbaum, M.A., Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J. Neurooncol. 83 (2007), 97–109.
White, E., et al. A Phase I trial of carboplatin administered by convection-enhanced delivery to patients with recurrent/progressive glioblastoma multiforme. Contemp. Clin. Trials 33 (2012), 320–331.
Siegal, T., Change clinical practice for brain tumor. Neuro Oncol. 15 (2013), 656–669.
Zhang, R., et al. Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models. Drug Deliv. 23 (2016), 2780–2786.
Yang, W., et al. Convection-enhanced delivery of carboplatin in combination with radiotherapy for the treatment of brain tumors. J. Neurooncol. 101 (2011), 379–390.
Jaaback, K., et al. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer (review). Cochrane Database Syst. Rev., 11, 2016, CD005340.
Jandial, D.A., et al. A Phase I pharmacokinetic study of intraperitoneal bortezomib and carboplatin in patients with persistent or recurrent ovarian cancer: an NRG Oncology/Gynecologic Oncology Group study. Gynecol. Oncol. 145 (2017), 236–242.
Scharovsky, O.G., et al. Metronomic chemotherapy: changing the paradigm that more is better. Curr. Oncol. 16 (2009), 7–15.
Zhidkov, N., et al. Continuous intraperitoneal carboplatin delivery for the treatment of late-stage ovarian cancer. Mol. Pharm. 10 (2013), 3315–3322.
Su, W.H., et al. Metronomic therapy for gynecologic cancers. Taiwan. J. Obstet. Gynecol. 51 (2012), 167–178.
Ye, H., et al. Sustained, low-dose intraperitoneal cisplatin improves treatment outcome in ovarian cancer mouse models. J. Control. Release 220 (2015), 358–367.
Pasquier, E., et al. Metronomic chemotherapy: new rationale for new directions. Nat. Rev. Clin. Oncol. 7 (2010), 455–465.
Kubota, H., et al. Feasibility of metronomic chemotherapy with tegafur-uracil, cisplatin, and dexamethasone for docetaxel-refractory prostate cancer. J. Rural Med. 12 (2017), 112–119.
Patil, V.M., et al. A prospective randomized Phase II study comparing metronomic chemotherapy with chemotherapy (single agent cisplatin), in patients with metastatic, relapsed or inoperable squamous cell carcinoma of head and neck. Oral Oncol. 51 (2015), 279–286.
Specenier, P., Vermorken, J.B., Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma. Expert Rev. Anticancer Ther. 18 (2018), 901–915.
Correale, P., et al. Phase II trial of bevacizumab and dose/dense chemotherapy with cisplatin and metronomic daily oral etoposide in advanced non-small-cell-lung cancer patients. Cancer Biol. Ther. 12 (2011), 112–118.
Tippayamontri, T., et al. Cellular uptake and cytoplasm/DNA distribution of cisplatin and oxaliplatin and their liposomal formulation in human colorectal cancer cell HCT116. Invest. New Drugs 29 (2011), 1321–1327.
Lajous, H., et al. Hybrid Gd3+/cisplatin cross-linked polymer nanoparticles enhance platinum accumulation and formation of DNA adducts in glioblastoma cell lines. Biomater. Sci. 6 (2018), 2386–2409.
Cullen, K.J., et al. Mitochondria as a critical target of the chemotherapeutic agent cisplatin in head and neck cancer. J. Bioenerg. Biomembr. 39 (2007), 43–50.
Van Gisbergen, M.W., et al. How do changes in the mtDNA and mitochondrial dysfunction influence cancer and cancer therapy? Challenges, opportunities and models. Mutat. Res. 764 (2015), 16–30.
Fonseca, S.B., et al. Rerouting chlorambucil to mitochondria combats drug deactivation and resistance in cancer cells. Chem. Biol. 18 (2011), 445–453.
Wisnovsky, S.P., et al. Targeting mitochondrial DNA with a platinum-based anticancer agent. Chem. Biol. 20 (2013), 1323–1328.
Gibson, D., Platinum(IV) anticancer prodrugs – hypotheses and facts. Dalton Trans. 45 (2016), 12983–12991.
Rocha, C.R.R., et al. Glutathione depletion sensitizes cisplatin- and temozolomide-resistant glioma cells in vitro and in vivo. Cell Death Dis., 5, 2014, e1505.
Villablanca, J.G., et al. A Phase I. new approaches to neuroblastoma therapy study of buthionine sulfoximine and melphalan with autologous stem cells for recurrent/refractory high-risk neuroblastoma. Pediatr. Blood Cancer 63 (2016), 1349–1356.
Vergote, I., et al. Phase 3 randomised study of canfosfamide (Telcyta ® , TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur. J. Cancer 45 (2009), 2324–2332.
Kaina, B., et al. Targeting O 6 -methylguanine-DNA methyltransferase with specific inhibitors as a strategy in cancer therapy. Cell. Mol. Life Sci. 67 (2010), 3663–3681.
Warren, K.E., et al. A Phase II study of O 6 -benzylguanine and temozolomide in pediatric patients with recurrent or progressive high-grade gliomas and brainstem gliomas: a Pediatric Brain Tumor Consortium study. J. Neurooncol. 106 (2012), 643–649.
Matei, D., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72 (2012), 2197–2205.
Garzon, R., et al. MicroRNAs in cancer. Annu. Rev. Med. 60 (2009), 167–179.
Visone, R., Croce, C.M., miRNAs and cancer. Am. J. Pathol. 174 (2009), 1131–1138.
Chen, W., et al. miR-136 targets E2F1 to reverse cisplatin chemosensitivity in glioma cells. J. Neurooncol. 120 (2014), 43–53.
Chen, X., et al. miR-873 acts as a novel sensitizer of glioma cells to cisplatin by targeting Bcl-2. Int. J. Oncol. 47 (2015), 1603–1611.
Ventola, C.L., Progress in nanomedicine: approved and investigational nanodrugs. Pharm. Ther. 42 (2017), 742–755.
Peer, D., et al. Nanocarriers as an emerging platform for cancer therapy. Nat. Nanotechnol. 2 (2007), 751–760.
Harper, B.W., et al. Advances in platinum chemotherapeutics. Chemistry 16 (2010), 7064–7077.
Cabral, H., Kataoka, K., Progress of drug-loaded polymeric micelles into clinical studies. J. Control. Release 190 (2014), 465–476.
Li, J., et al. Complex of cisplatin with biocompatible poly(ethylene glycol) with pendant carboxyl groups for the effective treatment of liver cancer. J. Appl. Polym. Sci. 131 (2014), 9246–9254.
Duan, X., et al. Polymeric micelle-mediated delivery of DNA-targeting organometallic complexes for resistant ovarian cancer treatment. Small 11 (2015), 3962–3972.
Johnstone, T.C., et al. The next generation of platinum drugs: targeted Pt(II) agents, nanoparticle delivery, and Pt(IV) prodrugs. Chem. Rev. 116 (2016), 3436–3486.
Parhizkar, M., et al. Electrohydrodynamic encapsulation of cisplatin in poly (lactic-co-glycolic acid) nanoparticles for controlled drug delivery. Nanomed. Nanotechnol. Biol. Med. 12 (2016), 1919–1929.
Xue, X., et al. Nanoscale drug delivery platforms overcome platinum-based resistance in cancer cells due to abnormal membrane protein trafficking. ACS Nano 7 (2013), 10452–10464.
Lehner, R., et al. Intelligent nanomaterials for medicine: carrier platforms and targeting strategies in the context of clinical application. Nanomed. Nanotechnol. Biol. Med. 9 (2013), 742–757.
Marrache, S., et al. Detouring of cisplatin to access mitochondrial genome for overcoming resistance. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), 10444–10449.
Sun, X., et al. A pH-responsive yolk-like nanoplatform for tumor targeted dual-mode magnetic resonance imaging and chemotherapy. ACS Nano 11 (2017), 7049–7059.
Cajot, S., et al. Design of reversibly core cross-linked micelles sensitive to reductive environment. J. Control. Release 152 (2011), 30–36.
Nishiyama, N., Kataoka, K., Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther. 112 (2006), 630–648.
Oerlemans, C., et al. Polymeric micelles in anticancer therapy: targeting, imaging and triggered release. Pharm. Res. 27 (2010), 2569–2589.
Stathopoulos, G.P., Boulikas, T., Lipoplatin formulation review article. J. Drug Deliv., 2012, 2012, 581363.
Patra, H.K., Turner, A.P.F., The potential legacy of cancer nanotechnology: cellular selection. Trends Biotechnol. 32 (2014), 21–31.
Li, S., et al. Overcoming resistance to cisplatin by inhibition of glutathione S-transferases (GSTs) with ethacraplatin micelles in vitro and in vivo. Biomaterials 144 (2017), 119–129.
Xu, S., et al. Supramolecular cisplatin–vorinostat nanodrug for overcoming drug resistance in cancer synergistic therapy. J. Control. Release 266 (2017), 36–46.
Krauze, M.T., et al. Real-time visualization and characterization of liposomal delivery into the monkey brain by magnetic resonance imaging. Brain Res. Protoc. 16 (2005), 20–26.
Zhang, C., et al. Convection enhanced delivery of cisplatin-loaded brain penetrating nanoparticles cures malignant glioma in rats. J. Control. Release 263 (2017), 112–119.
Saito, R., et al. Gadolinium-loaded liposomes allow for real-time magnetic resonance imaging of convection-enhanced delivery in the primate brain. Exp. Neurol. 196 (2005), 381–389.
Hillaireau, H., Couvreur, P., Nanocarriers’ entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66 (2009), 2873–2896.
Bregoli, L., et al. Nanomedicine applied to translational oncology: a future perspective on cancer treatment. Nanomed. Nanotechnol. Biol. Med. 12 (2016), 81–103.
Cai, Y., et al. Supramolecular “Trojan Horse” for nuclear delivery of dual anticancer drugs. J. Am. Chem. Soc. 139 (2017), 2876–2879.
Boulikas, T., Clinical overview on Lipoplatin™: a successful liposomal formulation of cisplatin. Expert Opin. Invest. Drugs 18 (2009), 1197–1218.
Exner, A.A., et al. Enhancement of carboplatin toxicity by pluronic block copolymers. J. Control. Release 106 (2005), 188–197.
Yang, T., et al. Anti-tumor efficiency of lipid-coated cisplatin nanoparticles co-loaded with microRNA-375. Theranostics 6 (2016), 142–154.
Hainfeld, J.F., et al. Gold nanoparticle imaging and radiotherapy of brain tumors in mice. Nanomedicine 8 (2013), 1601–1609.
McCarthy, J.R., Weissleder, R., Multifunctional magnetic nanoparticles for targeted imaging and therapy. Adv. Drug Deliv. Rev. 60 (2008), 1241–1251.
Zhu, H., et al. Responsive fluorescent Bi2O3@PVA hybrid nanogels for temperature-sensing, dual-modal imaging, and drug delivery. Biomaterials 33 (2012), 3058–3069.
Cao, Y., et al. Photo-triggered fluorescent theranostic prodrugs as DNA alkylating agents for mechlorethamine release and spatiotemporal monitoring. Org. Biomol. Chem. 13 (2015), 6742–6748.
Yuan, Y., et al. Targeted theranostic platinum(IV) prodrug with a built-in aggregation-induced emission light-up apoptosis sensor for noninvasive early evaluation of its therapeutic responses in situ. J. Am. Chem. Soc. 136 (2014), 2546–2554.
Choi, Y.M., et al. Mechanism of cisplatin-induced cytotoxicity is correlated to impaired metabolism due to mitochondrial ROS generation. PLoS One, 10, 2015, e0135083.
Mandal, R., et al. Mass spectrometry study of hemoglobin–oxaliplatin complexes in colorectal cancer patients and potential association with chemotherapeutic responses. Rapid Commun. Mass Spectrom. 20 (2006), 2533–2538.
